Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms
SGHT•Reimbursement progress for TearCare
- TearCare reimbursement progress was highlighted, with the first two Medicare Administrative Contractors establishing fee schedules to support market access.
Installed base and market size estimates
- Installed base was cited at more than 400,000 interventional glaucoma procedures and more than 75,000 interventional dry eye procedures performed to date.
- The dry eye market size was estimated at USD 2.4 billion in the US, versus a USD 6 billion addressable US glaucoma market with more than 4 million diagnosed patients.
Investor presentation outlines glaucoma and dry eye strategy
- Sight Sciences outlined a strategy to expand procedural eye-care offerings across glaucoma and dry eye, targeting earlier intervention versus daily eye drops.
- Management flagged a return to double-digit revenue growth in 2026, supported by strong gross margins and disciplined operating expense control.
